XLO ▲ +1.5% - Xilio Therapeutics, Inc.
$XLO - Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
26-OCT-2026 07:30 AM ET
Share this post
More filings for $XLO
XLO ▲ +0.6% - Xilio Therapeutics, Inc.Sep 28, 2026XLO - Xilio Therapeutics, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026
View full $XLO filing history →💬 Comments
Loading comments…
Leave a comment